{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:04:38Z","timestamp":1790759078018,"version":"4.1.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Estrogens are fundamental to bone health, exerting life-long effects onbone metabolism. They regulate skeletal growth and maturation during adolescence andmaintain bone remodeling in adulthood. The decline in estrogen levels during perimenopauseand postmenopause leads to bone mass loss. Emerging evidence also supports a role forprogestins in bone metabolism. Several estrogen-progestins formulations are available andwidely used for contraception in fertile women and as hormone replacement therapy (HRT) incases of primary or secondary ovarian insufficiency as well as in physiologic menopause.Advances in both synthetic and natural preparations allowed for more personalized treatmentapproaches. When selecting estrogen-progestin therapies, it is essential to consider their impacton bone health and remodelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This narrative review examines the effects of variousestrogen-progestin regimens on bone metabolism across the female lifespan, focusing on mechanisms of action, safety profiles, and clinical applications. Here we show that combined oralcontraceptives (COCs) are generally safe for bone mineral density (BMD) in adult women;however, caution is advised in adolescence, especially with very low-dose estrogen formulations.In hypogonadal women, postmenopausal hormone replacement therapy (HRT) is key forosteoporosis prevention. Physiological regimens, preferably transdermal estrogen at doseshigher than those used in typical postmenopausal therapy, may offer better bone protection.Additionally, oral gonadotropin-releasing hormone receptor (GnRH-R) antagonists combinedwith add-back therapy represent a novel long-term option for managing uterine fibroids andendometriosis without compromising BMD. In postmenopausal women, both HRT and selectiveestrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results &amp; implications<\/jats:title>\n                    <jats:p>Optimizing therapeutic strategies to balance efficacy and safety, iscritical to ensuring personalized care that preserves bone health and enhances quality of lifeacross a woman\u2019s lifespan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-025-02802-2","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:12:53Z","timestamp":1771405973000},"page":"2611-2626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of estroprogestin therapies on bone health from adolescence to postmenopause"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-8581","authenticated-orcid":false,"given":"Guabello","family":"G","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-5017","authenticated-orcid":false,"given":"Federici","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4477-4935","authenticated-orcid":false,"given":"Carrara","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5766-2657","authenticated-orcid":false,"given":"Ruotolo","family":"E","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-2146","authenticated-orcid":false,"given":"Rossi","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1373-650X","authenticated-orcid":false,"given":"Bertini","family":"J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-6074","authenticated-orcid":false,"given":"Bonomi","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-3278","authenticated-orcid":false,"given":"Grandi","family":"G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-3175","authenticated-orcid":false,"given":"Corbetta","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","volume":"97","author":"M Almeida","year":"2017","unstructured":"Almeida M, Laurent MR, Dubois V, Claessens F, O\u2019Brien CA, Bouillon R, Vanderschueren D, Manolagas SC (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135\u2013187. https:\/\/doi.org\/10.1152\/physrev.00033.2015","journal-title":"Physiol Rev"},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1359\/jbmr.1998.13.10.1602","volume":"13","author":"J Cadogan","year":"1998","unstructured":"Cadogan J, Blumsohn A, Barker ME, Eastell R (1998) A longitudinal study of bone gain in pubertal girls: anthropometric and biochemical correlates. J Bone Miner Res 13:1602\u20131612. https:\/\/doi.org\/10.1359\/jbmr.1998.13.10.1602","journal-title":"J Bone Miner Res"},{"key":"2802_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jbmr.2982","volume":"32","author":"L Gabel","year":"2017","unstructured":"Gabel L, Macdonald HM, McKay HA (2017) Sex differences and growth-related adaptations in bone microarchitecture, geometry, density, and strength from childhood to early adulthood: a mixed longitudinal HR-pQCT study. J Bone Miner Res 32:250\u2013263. https:\/\/doi.org\/10.1002\/jbmr.2982","journal-title":"J Bone Miner Res"},{"key":"2802_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature11000","volume":"485","author":"M Hayashi","year":"2012","unstructured":"Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H (2012) Osteoprotection by semaphorin 3A. Nature 485:69\u201374. https:\/\/doi.org\/10.1038\/nature11000","journal-title":"Nature"},{"key":"2802_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00306-4","volume":"12","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xie N, Sun X, Nice EC, Liou Y, Huang C et al (2024) Insights and implications of sexual dimorphism in osteoporosis. Bone Res 12:8. https:\/\/doi.org\/10.1038\/s41413-023-00306-4","journal-title":"Bone Res"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1210\/jc.2018-02047","volume":"38","author":"JC Lo","year":"2011","unstructured":"Lo JC, Burnett-Bowie SM, Finkelstein JS (2011) Bone and the perimenopause. Obstet Gynecol Clin North Am 38:503\u2013517. https:\/\/doi.org\/10.1210\/jc.2018-02047","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2802_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jc.2011-3362","volume":"15","author":"SD Harlow","year":"2012","unstructured":"Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ, STRAW+10 Collaborative Group (2012) Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric 15:105\u2013114. https:\/\/doi.org\/10.1210\/jc.2011-3362","journal-title":"Climacteric"},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-g","volume":"166","author":"RL Barbieri","year":"1992","unstructured":"Barbieri RL (1992) Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 166:740\u2013745. https:\/\/doi.org\/10.1016\/0002-9378(92)91706-g","journal-title":"Am J Obstet Gynecol"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s00198-019-05103-6","volume":"30","author":"P Hadji","year":"2019","unstructured":"Hadji P, Colli E, Regidor PA (2019) Bone health in estrogen-free contraception. Osteoporos Int 30:2391\u20132400. https:\/\/doi.org\/10.1007\/s00198-019-05103-6","journal-title":"Osteoporos Int"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13697130410001713788","volume":"7","author":"A Bagur","year":"2004","unstructured":"Bagur A, Oliveri B, Mautalen C, Belotti M, Mastaglia S, Yankelevich D, Sayegh F, Royer M (2004) Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women. Climacteric 7:181\u2013188. https:\/\/doi.org\/10.1080\/13697130410001713788","journal-title":"Climacteric"},{"key":"2802_CR11","first-page":"77","volume":"37","author":"RA Lobo","year":"1992","unstructured":"Lobo RA, Cassidenti DL (1992) Pharmacokinetics of oral 17 beta-estradiol. J Reprod Med 37:77\u201384","journal-title":"J Reprod Med"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000180039","volume":"21","author":"B D\u00fcsterberg","year":"1985","unstructured":"D\u00fcsterberg B, Schmidt-Gollwitzer M, H\u00fcmpel M (1985) Pharmacokinetics and biotransformation of estradiol valerate in ovariectomized women. Horm Res 21:145\u2013154. https:\/\/doi.org\/10.1159\/000180039","journal-title":"Horm Res"},{"key":"2802_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0378-5122(90)90013-v","volume":"12","author":"AR Aedo","year":"1990","unstructured":"Aedo AR, Landgren BM, Diczfalusy E (1990) Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women. Maturitas 12:333\u2013343. https:\/\/doi.org\/10.1016\/0378-5122(90)90013-v","journal-title":"Maturitas"},{"key":"2802_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/17512433.2020.1750365","volume":"13","author":"G Grandi","year":"2020","unstructured":"Grandi G, Del Savio MC, da Lopes Silva-Filho A, Facchinetti F (2020) Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol 13:327\u2013330. https:\/\/doi.org\/10.1080\/17512433.2020.1750365","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/13697137.2022.2139599","volume":"26","author":"J Douxfils","year":"2023","unstructured":"Douxfils J, Gaspard U, Taziaux M, Jost M, Bouvy C, Lobo RA, Utian WH, Foidart JM (2023) Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric 26:55\u201363. https:\/\/doi.org\/10.1080\/13697137.2022.2139599","journal-title":"Climacteric"},{"key":"2802_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769187","volume":"12","author":"L Morimont","year":"2021","unstructured":"Morimont L, Haguet H, Dogn\u00e9 J, Gaspard U, Douxfils J (2021) Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne) 12:769187. https:\/\/doi.org\/10.3389\/fendo.2021.769187","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2802_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3181\/00379727-217-44199","volume":"217","author":"BR Bhavnani","year":"1998","unstructured":"Bhavnani BR (1998) Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 217:6\u201316. https:\/\/doi.org\/10.3181\/00379727-217-44199","journal-title":"Proc Soc Exp Biol Med"},{"key":"2802_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-11-0560","volume":"166","author":"AL Isotton","year":"2012","unstructured":"Isotton AL, Wender MCO, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207\u2013213. https:\/\/doi.org\/10.1530\/EJE-11-0560","journal-title":"Eur J Endocrinol"},{"key":"2802_CR19","first-page":"133","volume":"4","author":"K Fotherby","year":"1982","unstructured":"Fotherby K (1982) Pharmacokinetics of ethynyloestradiol in humans. Methods Find Exp Clin Pharmacol 4:133\u2013141","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2802_CR20","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/845180","volume":"2010","author":"V Seifert-Klauss","year":"2010","unstructured":"Seifert-Klauss V, Prior JC (2010) Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010:845180. https:\/\/doi.org\/10.4061\/2010\/845180","journal-title":"J Osteoporos"},{"key":"2802_CR21","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1210\/jcem-70-5-1431","volume":"70","author":"HK Nielsen","year":"1990","unstructured":"Nielsen HK, Brixen K, Bouillon R, Mosekilde L (1990) Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 70:1431\u20131437. https:\/\/doi.org\/10.1210\/jcem-70-5-1431","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR22","first-page":"996","volume":"78","author":"BM Biller","year":"1991","unstructured":"Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996\u20131001","journal-title":"Obstet Gynecol"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJM199011013231801","volume":"323","author":"JC Prior","year":"1990","unstructured":"Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221\u20131227. https:\/\/doi.org\/10.1056\/NEJM199011013231801","journal-title":"N Engl J Med"},{"key":"2802_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/8756-3282(95)00487-4","volume":"18","author":"JC Prior","year":"1996","unstructured":"Prior JC, Vigna YM, Barr SI, Kennedy S, Schulzer M, Li DK (1996) Ovulatory premenopausal women lose cancellous spinal bone: a five year-prospective study. Bone 18:261\u2013267. https:\/\/doi.org\/10.1016\/8756-3282(95)00487-4","journal-title":"Bone"},{"key":"2802_CR25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/ajcn\/86.5.1791","volume":"86","author":"EJ Waugh","year":"2007","unstructured":"Waugh EJ, Polivy J, Ridout R, Hawker GA (2007) A prospective investigation of the relations among cognitive dietary restraint, subclinical ovulatory disturbances, physical activity, and bone mass in healthy young women. Am J Clin Nutr 86:1791\u20131801. https:\/\/doi.org\/10.1093\/ajcn\/86.5.1791","journal-title":"Am J Clin Nutr"},{"key":"2802_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1210\/jcem.81.2.8636286","volume":"81","author":"K Waller","year":"1996","unstructured":"Waller K, Reim J, Fenster L, Swan SH, Brumback B, Windham GC, Lasley B, Ettinger B, Marcus R (1996) Bone mass and subtle abnormalities in ovulatory function in healthy women. J Clin Endocrinol Metab 81:663\u2013668. https:\/\/doi.org\/10.1210\/jcem.81.2.8636286","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR27","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1210\/jc.2009-2497","volume":"95","author":"JL Bedford","year":"2010","unstructured":"Bedford JL, Prior JC, Barr SI (2010) A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol, and change in bone density over two years in healthy young women. J Clin Endocrinol Metab 95:3291\u20133299. https:\/\/doi.org\/10.1210\/jc.2009-2497","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0002-9343(94)90092-2","volume":"96","author":"JC Prior","year":"1994","unstructured":"Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC (1994) Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med 96:521\u2013530. https:\/\/doi.org\/10.1016\/0002-9343(94)90092-2","journal-title":"Am J Med"},{"key":"2802_CR29","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1210\/jc.2007-0066","volume":"92","author":"GE Hale","year":"2007","unstructured":"Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS (2007) Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab 92:3060\u20133067. https:\/\/doi.org\/10.1210\/jc.2007-0066","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR30","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1359\/jbmr.1997.12.11.1851","volume":"12","author":"JC Prior","year":"1997","unstructured":"Prior JC, Vigna YM, Wark D, Eyre DR, Lentle BC, Li DK et al (1997) Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 12:1851\u20131863. https:\/\/doi.org\/10.1359\/jbmr.1997.12.11.1851","journal-title":"J Bone Miner Res"},{"key":"2802_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","volume":"276","author":"P Trial","year":"1996","unstructured":"Trial P (1996) Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen\/progestin interventions (PEPI) trial. JAMA 276:1389\u20131396. https:\/\/doi.org\/10.1001\/jama.1996.03540170033029","journal-title":"JAMA"},{"key":"2802_CR32","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","volume":"287","author":"R Lindsay","year":"2002","unstructured":"Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668\u20132676. https:\/\/doi.org\/10.1001\/jama.287.20.2668","journal-title":"JAMA"},{"key":"2802_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/er.2012-1008","volume":"34","author":"FZ Stanczyk","year":"2013","unstructured":"Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (2013) Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 34:171\u2013208. https:\/\/doi.org\/10.1210\/er.2012-1008","journal-title":"Endocr Rev"},{"key":"2802_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.contraception.2007.11.005","volume":"77","author":"MA Vandever","year":"2008","unstructured":"Vandever MA, Kuehl TJ, Sulak PJ, Witt I, Coffee A, Wincek TJ, Reape KZ (2008) Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 77:162\u2013170. https:\/\/doi.org\/10.1016\/j.contraception.2007.11.005","journal-title":"Contraception"},{"key":"2802_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0002-9378(99)70364-9","volume":"18","author":"P Coney","year":"1999","unstructured":"Coney P, DelConte A (1999) The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol. Am J Obstet Gynecol 18:53\u201358. https:\/\/doi.org\/10.1016\/s0002-9378(99)70364-9","journal-title":"Am J Obstet Gynecol"},{"key":"2802_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/humrep\/der058","volume":"26","author":"S Christin-Maitre","year":"2011","unstructured":"Christin-Maitre S, Serfaty D, Chabbert-Buffet N, Ochsenbein E, Chassard D, Thomas J-L (2011) Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17\u03b2-estradiol (NOMAC\/E2): a double-blind, randomized study. Hum Reprod 26:1338\u20131347. https:\/\/doi.org\/10.1093\/humrep\/der058","journal-title":"Hum Reprod"},{"key":"2802_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.contraception.2012.07.008","volume":"87","author":"J Endrikat","year":"2013","unstructured":"Endrikat J, Parke S, Trummer D, Serrani M, Duijkers I, Klipping C (2013) Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception 87:227\u2013234. https:\/\/doi.org\/10.1016\/j.contraception.2012.07.008","journal-title":"Contraception"},{"key":"2802_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.contraception.2021.03.003","volume":"103","author":"I Duijkers","year":"2021","unstructured":"Duijkers I, Klipping C, Kinet V, Jost M, Bastidas A, Foidart J (2021) Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Contraception 103:386\u2013393. https:\/\/doi.org\/10.1016\/j.contraception.2021.03.003","journal-title":"Contraception"},{"key":"2802_CR39","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.fertnstert.2014.03.004","volume":"101","author":"D Apter","year":"2014","unstructured":"Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C (2014) Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril 101:1656-1662.e1-4. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.03.004","journal-title":"Fertil Steril"},{"key":"2802_CR40","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1177\/0091270011423664","volume":"52","author":"C Klipping","year":"2012","unstructured":"Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S et al (2012) Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 52:1704\u20131713. https:\/\/doi.org\/10.1177\/0091270011423664","journal-title":"J Clin Pharmacol"},{"key":"2802_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/humrep\/14.4.982","volume":"14","author":"CF Rice","year":"1999","unstructured":"Rice CF, Killick SR, Dieben T, Coelingh Bennink H (1999) A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 14:982\u2013985. https:\/\/doi.org\/10.1093\/humrep\/14.4.982","journal-title":"Hum Reprod"},{"key":"2802_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/13625187.2015.1044082","volume":"20","author":"IJM Duijkers","year":"2015","unstructured":"Duijkers IJM, Heger-Mahn D, Drouin D, Skouby S (2015) A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24\/4 regimen. Eur J Contracept Reprod Health Care 20:419\u2013427. https:\/\/doi.org\/10.3109\/13625187.2015.1044082","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2802_CR43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1210\/jc.2007-2201","volume":"93","author":"JS Walsh","year":"2008","unstructured":"Walsh JS, Eastell R, Peel NF (2008) Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab 93:1317\u20131323. https:\/\/doi.org\/10.1210\/jc.2007-2201","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010061","volume":"18","author":"A Tassi","year":"2025","unstructured":"Tassi A, Londero AP, Xholli A, Lanzolla G, Bertozzi S, Savelli L, Prefumo F, Cagnacci A (2025) Hormonal contraception and bone metabolism: emerging evidence from a systematic review and meta-analysis of studies on post-pubertal and reproductive-age women. Pharmaceuticals (Basel) 18:61. https:\/\/doi.org\/10.3390\/ph18010061","journal-title":"Pharmaceuticals (Basel)"},{"key":"2802_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jadohealth.2004.07.005","volume":"35","author":"BA Cromer","year":"2004","unstructured":"Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J, Debanne SM (2004) Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35:434\u2013441. https:\/\/doi.org\/10.1016\/j.jadohealth.2004.07.005","journal-title":"J Adolesc Health"},{"key":"2802_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006033.pub5","author":"LM Lopez","year":"2014","unstructured":"Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M (2014) Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006033.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"2802_CR47","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/AOG.0000000000003414","volume":"134","author":"T Raine-Bennett","year":"2019","unstructured":"Raine-Bennett T, Chandra M, Armstrong MA, Alexeeff S, Lo JC (2019) Depot medroxyprogesterone acetate, oral contraceptive, intrauterine device use, and fracture risk. Obstet Gynecol 134:581\u2013589. https:\/\/doi.org\/10.1097\/AOG.0000000000003414","journal-title":"Obstet Gynecol"},{"key":"2802_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4183\/aeb.2022.355","volume":"18","author":"C Ampatzis","year":"2022","unstructured":"Ampatzis C, Zervoudis S, Iatrakis G, Mastorakos G (2022) Effect of oral contraceptives on bone mineral density. Acta Endocrinol (Buchar) 18:355\u2013360. https:\/\/doi.org\/10.4183\/aeb.2022.355","journal-title":"Acta Endocrinol (Buchar)"},{"key":"2802_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0012-7","volume":"15","author":"TP Biason","year":"2015","unstructured":"Biason TP, Goldberg TB, Kurokawa CS, Moretto MR, Teixeira AS, Nunes HRdC (2015) Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period. BMC Endocr Disord 15:15. https:\/\/doi.org\/10.1186\/s12902-015-0012-7","journal-title":"BMC Endocr Disord"},{"key":"2802_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.contraception.2011.08.003","volume":"85","author":"D Mansour","year":"2012","unstructured":"Mansour D (2012) The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception 85:224\u2013234. https:\/\/doi.org\/10.1016\/j.contraception.2011.08.003","journal-title":"Contraception"},{"key":"2802_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jpag.2009.11.001","volume":"23","author":"H Agostino","year":"2010","unstructured":"Agostino H, Di Meglio G (2010) Low-dose oral contraceptives in adolescents: how low can you go? J Pediatr Adolesc Gynecol 23:195\u2013201. https:\/\/doi.org\/10.1016\/j.jpag.2009.11.001","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2802_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/cen.13932","volume":"90","author":"A Goshtasebi","year":"2019","unstructured":"Goshtasebi A, Subotic Brajic T, Scholes D, Beres Lederer Goldberg T, Berenson A, Prior JC (2019) Adolescent use of combined hormonal contraception and peak bone mineral density accrual: a meta-analysis of international prospective controlled studies. Clin Endocrinol (Oxf) 90:517\u2013524. https:\/\/doi.org\/10.1111\/cen.13932","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2802_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.contraception.2008.05.002","volume":"78","author":"E Pikkarainen","year":"2008","unstructured":"Pikkarainen E, Lehtonen-Veromaa M, M\u00f6tt\u00f6nen T, Kautiainen H, Viikari J (2008) Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception 78:226\u2013231. https:\/\/doi.org\/10.1016\/j.contraception.2008.05.002","journal-title":"Contraception"},{"key":"2802_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.23736\/S2724-606X.20.04688-2","volume":"73","author":"ML Rocca","year":"2021","unstructured":"Rocca ML, Palumbo AR, Bitonti G, Brisinda C, Di Carlo C (2021) Bone health and hormonal contraception. Minerva Obstet Gynecol 73:678\u2013696. https:\/\/doi.org\/10.23736\/S2724-606X.20.04688-2","journal-title":"Minerva Obstet Gynecol"},{"key":"2802_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00603","volume":"11","author":"LK Bachrach","year":"2020","unstructured":"Bachrach LK (2020) Hormonal contraception and bone health in adolescents. Front Endocrinol (Lausanne) 11:603. https:\/\/doi.org\/10.3389\/fendo.2020.00603","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2802_CR56","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/00006254-200211000-00022","volume":"57","author":"JS Laven","year":"2002","unstructured":"Laven JS, Imani B, Eijkemans MJ, Fauser BC (2002) New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 57:755\u2013767. https:\/\/doi.org\/10.1097\/00006254-200211000-00022","journal-title":"Obstet Gynecol Surv"},{"key":"2802_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/jcem-52-1-156.38","volume":"52","author":"RA Lobo","year":"1981","unstructured":"Lobo RA, Granger L, Goebelsmann U, Mishell DR Jr (1981) Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO. J Clin Endocrinol Metab 52:156\u2013158. https:\/\/doi.org\/10.1210\/jcem-52-1-156.38","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3109\/09513590.2010.495797","volume":"27","author":"MC Amato","year":"2011","unstructured":"Amato MC, Verghi M, Nucera M, Galluzzo A, Giordano C (2011) Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome. Gynecol Endocrinol 27:579\u2013586. https:\/\/doi.org\/10.3109\/09513590.2010.495797","journal-title":"Gynecol Endocrinol"},{"key":"2802_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316689","volume":"24","author":"C Marie","year":"2023","unstructured":"Marie C, Pierre A, Mayeur A, Giton F, Corre R, Grynberg M et al (2023) Dysfunction of human estrogen signaling as a novel molecular signature of polycystic ovary syndrome. Int J Mol Sci 24:16689. https:\/\/doi.org\/10.3390\/ijms242316689","journal-title":"Int J Mol Sci"},{"key":"2802_CR60","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1530\/EJE-11-1047","volume":"166","author":"D Cibula","year":"2012","unstructured":"Cibula D, Skrenkova J, Hill M, Stepan JJ (2012) Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. Eur J Endocrinol 166:1003\u20131011. https:\/\/doi.org\/10.1530\/EJE-11-1047","journal-title":"Eur J Endocrinol"},{"key":"2802_CR61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2023.2216294","volume":"18","author":"JC Prior","year":"2023","unstructured":"Prior JC, Shirin S, Goshtasebi A (2023) Bone health and prevalent fractures in women with polycystic ovary syndrome: a meta-analysis and endocrine-context pathophysiology review. Expert Rev Endocrinol Metab 18:283\u2013293. https:\/\/doi.org\/10.1080\/17446651.2023.2216294","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2802_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1163771","volume":"14","author":"EG Mills","year":"2023","unstructured":"Mills EG, Abbara A, Dhillo WS, Comninos AN (2023) Effects of distinct polycystic ovary syndrome phenotypes on bone health. Front Endocrinol (Lausanne) 14:1163771. https:\/\/doi.org\/10.3389\/fendo.2023.1163771","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2802_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2265.1998.3691182.x","volume":"48","author":"S Adami","year":"1998","unstructured":"Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol (Oxf) 48:169\u2013173. https:\/\/doi.org\/10.1046\/j.1365-2265.1998.3691182.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2802_CR64","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 108:2447\u20132469. https:\/\/doi.org\/10.1210\/clinem\/dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jpag.2020.01.003","volume":"33","author":"NH Golden","year":"2020","unstructured":"Golden NH (2020) Bones and birth control in adolescent girls. J Pediatr Adolesc Gynecol 33:249\u2013254. https:\/\/doi.org\/10.1016\/j.jpag.2020.01.003","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2802_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0889-8545(05)70190-x","volume":"28","author":"JV Zborowski","year":"2001","unstructured":"Zborowski JV, Talbott EO, Cauley JA (2001) Polycystic ovary syndrome, androgen excess, and the impact on bone. Obstet Gynecol Clin North Am 28:135. https:\/\/doi.org\/10.1016\/s0889-8545(05)70190-x","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2802_CR67","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1055\/s-2007-1000771","volume":"26","author":"J Prezelj","year":"1994","unstructured":"Prezelj J, Kocijancic A (1994) Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess. Horm Metab Res 26:46\u201348","journal-title":"Horm Metab Res"},{"key":"2802_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpag.2011.11.010","volume":"25","author":"S Bechtold","year":"2012","unstructured":"Bechtold S, Dalla Pozza R, Putzker S, Roeb J, Buckel M, Weissenbacher C, Schmidt H (2012) Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 25:175\u2013180. https:\/\/doi.org\/10.1016\/j.jpag.2011.11.010","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2802_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.maturitas.2005.10.007","volume":"54","author":"M Gambacciani","year":"2006","unstructured":"Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR (2006) Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 54:176\u2013180. https:\/\/doi.org\/10.1016\/j.maturitas.2005.10.007","journal-title":"Maturitas"},{"key":"2802_CR70","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/IJWH.S288070","volume":"14","author":"G Grandi","year":"2022","unstructured":"Grandi G, Di Vinci P, Sgandurra A, Feliciello L, Monari F, Facchinetti F (2022) Contraception during perimenopause: practical guidance. Int J Womens Health 14:913\u2013929. https:\/\/doi.org\/10.2147\/IJWH.S288070","journal-title":"Int J Womens Health"},{"key":"2802_CR71","doi-asserted-by":"publisher","DOI":"10.15761\/FWH.1000178","volume":"5","author":"J Dinger","year":"2020","unstructured":"Dinger J, M\u00f6hner S, Heinemann K (2020) Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: results from the extended INAS-SCORE study. Frontiers in Women\u2019s Health 5:1. https:\/\/doi.org\/10.15761\/FWH.1000178","journal-title":"Frontiers in Women\u2019s Health"},{"key":"2802_CR72","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA (2021) Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med 384:630\u2013642. https:\/\/doi.org\/10.1056\/NEJMoa2008283","journal-title":"N Engl J Med"},{"key":"2802_CR73","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-022-01790-4","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY (2022) Relugolix\/Estradiol\/Norethisterone (Norethindrone) acetate: a review in symptomatic uterine fibroids. Drugs 82:1549\u20131556. https:\/\/doi.org\/10.1007\/s40265-022-01790-4","journal-title":"Drugs"},{"key":"2802_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2441981","author":"M Barretta","year":"2024","unstructured":"Barretta M, Vignali M, La Marca A, Grandi G (2024) The oral GnRH antagonists, a new class of drugs in gynaecology: from pharmacokinetics to possible clinical applications. Expert Opin Drug Metab Toxicol. https:\/\/doi.org\/10.1080\/17425255.2024.2441981","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2802_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1464803","volume":"15","author":"S Federici","year":"2024","unstructured":"Federici S, Rossetti R, Moleri S, Munari EV, Frixou M, Bonomi M, Persani L (2024) Primary ovarian insufficiency: update on clinical and genetic findings. Front Endocrinol (Lausanne) 15:1464803. https:\/\/doi.org\/10.3389\/fendo.2024.1464803","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2802_CR76","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/hropen\/hoae065","volume":"27","author":"N Panay","year":"2024","unstructured":"Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, Gravholt CH, Kalantaridou S, Kallen A, Kim KQ, Misrahi M, Mousa A, Nappi RE, Rocca WA, Ruan X, Teede H, Vermeulen N, Vogt E, Vincent AJ, ESHRE, ASRM, CREWHIRL, IMS Guideline Group on POI (2024) Evidence-based guideline: premature ovarian insufficiency. Climacteric 27:510\u2013520. https:\/\/doi.org\/10.1093\/hropen\/hoae065","journal-title":"Climacteric"},{"key":"2802_CR77","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/cen.15097","volume":"101","author":"CN Jayasena","year":"2024","unstructured":"Jayasena CN, Devine K, Barber K, Comninos AN, Conway GS, Crown A, Davies MC, Ewart A, Seal LJ, Smyth A, Turner HE, Webber L, Anderson RA, Quinton R (2024) Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism. Clin Endocrinol 101:409\u2013442. https:\/\/doi.org\/10.1111\/cen.15097","journal-title":"Clin Endocrinol"},{"key":"2802_CR78","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/13697137.2020.1804547","volume":"23","author":"N Panay","year":"2020","unstructured":"Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, Wolfman W (2020) Premature ovarian insufficiency: an International Menopause Society white paper. Climacteric 23:426\u2013446. https:\/\/doi.org\/10.1080\/13697137.2020.1804547","journal-title":"Climacteric"},{"key":"2802_CR79","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2008-1878","volume":"94","author":"VB Popat","year":"2009","unstructured":"Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94:2277\u20132283. https:\/\/doi.org\/10.1210\/jc.2008-1878","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR80","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1210\/jc.2015-4063","volume":"101","author":"B Cartwright","year":"2016","unstructured":"Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J (2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 101:3497\u20133505. https:\/\/doi.org\/10.1210\/jc.2015-4063","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR81","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2265.2010.03868.x","volume":"73","author":"PM Crofton","year":"2010","unstructured":"Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HOD, Kelnar CJ, Wallace WH (2010) Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 73:707\u2013714. https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03868.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2802_CR82","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/GME.0000000000001921","volume":"29","author":"A Fine","year":"2022","unstructured":"Fine A, Busza A, Allen LM, Kelly C, Wolfman W, Jacobson M, Lega IC (2022) Comparing estrogen-based hormonal contraceptives and hormone therapy on bone mineral density in women with premature ovarian insufficiency: a systematic review. Menopause 29:351\u2013359. https:\/\/doi.org\/10.1097\/GME.0000000000001921","journal-title":"Menopause"},{"key":"2802_CR83","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12020-016-1046-y","volume":"55","author":"D Cintron","year":"2017","unstructured":"Cintron D, Rodriguez-Gutierrez R, Serrano V, Latortue-Albino P, Erwin PJ, Murad MH (2017) Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis. Endocrine 55:366\u2013375. https:\/\/doi.org\/10.1007\/s12020-016-1046-y","journal-title":"Endocrine"},{"key":"2802_CR84","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2022.09.011","volume":"167","author":"GPO Costa","year":"2023","unstructured":"Costa GPO, Ferreira-Filho ES, Simoes RDS, Soares-Junior JM, Baracat EC, Maciel GAR (2023) Impact of hormone therapy on the bone density of women with premature ovarian insufficiency: a systematic review. Maturitas 167:105\u2013112. https:\/\/doi.org\/10.1016\/j.maturitas.2022.09.011","journal-title":"Maturitas"},{"key":"2802_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1530\/EJE-16-0582","volume":"176","author":"L Cleemann","year":"2017","unstructured":"Cleemann L, Holm K, Kobbernagel H, Kristensen B, Skouby SO, Jensen AK et al (2017) Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial. Eur J Endocrinol 176:233\u2013242. https:\/\/doi.org\/10.1530\/EJE-16-0582","journal-title":"Eur J Endocrinol"},{"key":"2802_CR86","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4158\/EP161622.OR","volume":"23","author":"F Zaiem","year":"2017","unstructured":"Zaiem F, Alahdab F, Nofal AA, Murad MH, Javed A (2017) Oral versus transdermal estrogen in Turner syndrome: a systematic review and meta-analysis. Endocr Pract 23:408\u2013421. https:\/\/doi.org\/10.4158\/EP161622.OR","journal-title":"Endocr Pract"},{"key":"2802_CR87","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-010-1170-0","volume":"21","author":"CR Holroyd","year":"2010","unstructured":"Holroyd CR, Davies JH, Taylor P, Jameson K, Rivett C, Cooper C et al (2010) Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int 21:2093\u20132099. https:\/\/doi.org\/10.1007\/s00198-010-1170-0","journal-title":"Osteoporos Int"},{"key":"2802_CR88","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1210\/jc.2018-00854","volume":"103","author":"HH Nguyen","year":"2018","unstructured":"Nguyen HH, Wong P, Strauss BJ, Ebeling PR, Milat F, Vincent A (2018) A cross-sectional and longitudinal analysis of trabecular bone score in adults with Turner syndrome. J Clin Endocrinol Metab 103:3792\u20133800. https:\/\/doi.org\/10.1210\/jc.2018-00854","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR89","doi-asserted-by":"publisher","first-page":"G53","DOI":"10.1093\/ejendo\/lvae050","volume":"190","author":"CH Gravholt","year":"2024","unstructured":"Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A et al (2024) Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol 190:G53\u2013G151. https:\/\/doi.org\/10.1093\/ejendo\/lvae050","journal-title":"Eur J Endocrinol"},{"key":"2802_CR90","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1249\/mss.0b013e318149f111","volume":"39","author":"A Nattiv","year":"2007","unstructured":"Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP, American College of Sports Medicine (2007) American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 39:1867\u20131882. https:\/\/doi.org\/10.1249\/mss.0b013e318149f111","journal-title":"Med Sci Sports Exerc"},{"key":"2802_CR91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3810\/psm.2011.02.1871","volume":"39","author":"KE Ackerman","year":"2011","unstructured":"Ackerman KE, Misra M (2011) Bone health and the female athlete triad in adolescent athletes. Phys Sportsmed 39:131\u2013141. https:\/\/doi.org\/10.3810\/psm.2011.02.1871","journal-title":"Phys Sportsmed"},{"key":"2802_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsem-2021-001112","volume":"7","author":"K Aalberg","year":"2021","unstructured":"Aalberg K, Stavem K, Norheim F, Russell MB, Chaibi A (2021) Effect of oral and transdermal oestrogen therapy on bone mineral density in functional hypothalamic amenorrhoea: a systematic review and meta-analysis. BMJ Open Sport Exerc Med 7:e001112. https:\/\/doi.org\/10.1136\/bmjsem-2021-001112","journal-title":"BMJ Open Sport Exerc Med"},{"key":"2802_CR93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/bjsports-2018-099723","volume":"53","author":"KE Ackerman","year":"2019","unstructured":"Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M (2019) Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med 53:229\u2013236. https:\/\/doi.org\/10.1136\/bjsports-2018-099723","journal-title":"Br J Sports Med"},{"key":"2802_CR94","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/jbmr.447","volume":"26","author":"M Misra","year":"2011","unstructured":"Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A (2011) Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 26:2430\u20132438. https:\/\/doi.org\/10.1002\/jbmr.447","journal-title":"J Bone Miner Res"},{"key":"2802_CR95","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1210\/jc.2017-00131","volume":"102","author":"CM Gordon","year":"2017","unstructured":"Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M et al (2017) Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102:1413\u20131439. https:\/\/doi.org\/10.1210\/jc.2017-00131","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-0041-1730289","volume":"43","author":"AR Coelho","year":"2021","unstructured":"Coelho AR, Cardoso G, Brito ME, Gomes IN, Cascais MJ (2021) The female athlete triad\/relative energy deficiency in sports (RED-S). Rev Bras Ginecol Obstet 43:395\u2013402. https:\/\/doi.org\/10.1055\/s-0041-1730289","journal-title":"Rev Bras Ginecol Obstet"},{"key":"2802_CR97","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40618-018-0978-x","volume":"42","author":"L Vignozzi","year":"2019","unstructured":"Vignozzi L, Malavolta N, Villa P, Mangili G, Migliaccio S, Lello S (2019) Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. J Endocrinol Invest 42:609\u2013618. https:\/\/doi.org\/10.1007\/s40618-018-0978-x","journal-title":"J Endocrinol Invest"},{"key":"2802_CR98","doi-asserted-by":"publisher","first-page":"G49","DOI":"10.1093\/ejendo\/lvaf206","volume":"193","author":"MA Lumsden","year":"2025","unstructured":"Lumsden MA, Dekkers OM, Faubion SS, Lind\u00e9n Hirschberg A, Jayasena CN, Lambrinoudaki I et al (2025) European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur J Endocrinol 193:G49\u2013G81. https:\/\/doi.org\/10.1093\/ejendo\/lvaf206","journal-title":"Eur J Endocrinol"},{"key":"2802_CR99","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 105:dgaa048. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR100","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR101","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/s8756-3282(01)00706-2","volume":"30","author":"SJM Neele","year":"2002","unstructured":"Neele SJM, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599\u2013603. https:\/\/doi.org\/10.1016\/s8756-3282(01)00706-2","journal-title":"Bone"},{"key":"2802_CR102","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"J Blake","year":"2021","unstructured":"Blake J, Cosman FA, Lewiecki EM, McClung MR, Pinkerton J, Shapiro M (2021) Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28:973\u2013997. https:\/\/doi.org\/10.1097\/GME.0000000000001831","journal-title":"Menopause"},{"key":"2802_CR103","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate\u2013results from a randomized double-blind placebo-controlled trial. Bone 50:1389\u20131393. https:\/\/doi.org\/10.1016\/j.bone.2012.03.016","journal-title":"Bone"},{"key":"2802_CR104","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.mayocp.2016.09.018","volume":"92","author":"I Goldstein","year":"2017","unstructured":"Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ et al (2017) Hypoactive sexual desire disorder: International Society for the Study of Women\u2019s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 92:114\u2013128. https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.018","journal-title":"Mayo Clin Proc"},{"key":"2802_CR105","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1210\/jc.2004-1747","volume":"90","author":"J Simon","year":"2005","unstructured":"Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226\u20135233. https:\/\/doi.org\/10.1210\/jc.2004-1747","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR106","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0378-5122(94)00898-h","volume":"21","author":"SR Davis","year":"1995","unstructured":"Davis SR, McCloud P, Strauss BJG, Burger H (1995) Testosterone enhances estradiol\u2019s effects on postmenopausal bone density and sexuality. Maturitas 21:227\u2013236. https:\/\/doi.org\/10.1016\/0378-5122(94)00898-h","journal-title":"Maturitas"},{"key":"2802_CR107","first-page":"1012","volume":"44","author":"E Barrett-Connor","year":"1999","unstructured":"Barrett-Connor E, Young R, Notelovitz M, Wiita B, Yang HM, Nolan J (1999) A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 44:1012\u20131020","journal-title":"J Reprod Med"},{"key":"2802_CR108","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0029-7844(94)00448-m","volume":"85","author":"NB Watts","year":"1995","unstructured":"Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ (1995) Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 85:529\u2013537. https:\/\/doi.org\/10.1016\/0029-7844(94)00448-m","journal-title":"Obstet Gynecol"},{"key":"2802_CR109","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1210\/jc.2005-2596","volume":"91","author":"KK Miller","year":"2006","unstructured":"Miller KK, Biller BM, Beauregard C, Lipman JG, Jones J, Schoenfeld D et al (2006) Effects of testosterone replacement in androgen deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91:1683\u20131690. https:\/\/doi.org\/10.1210\/jc.2005-2596","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR110","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1210\/jc.2013-4145","volume":"99","author":"VB Popat","year":"2014","unstructured":"Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF et al (2014) Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 99:3418\u20133426. https:\/\/doi.org\/10.1210\/jc.2013-4145","journal-title":"J Clin Endocrinol Metab"},{"key":"2802_CR111","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/17425255.2023.2279752","volume":"19","author":"C Battipaglia","year":"2023","unstructured":"Battipaglia C, Feliciello L, Genazzani AD, Facchinetti F, Grandi G (2023) Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. Expert Opin Drug Metab Toxicol 19:871\u2013879. https:\/\/doi.org\/10.1080\/17425255.2023.2279752","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2802_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009849.pub3","volume":"2015","author":"LM Lopez","year":"2015","unstructured":"Lopez LM, Chen M, Mullins Long S, Curtis KM, Helmerhorst FM (2015) Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database Syst Rev 2015:CD009849. https:\/\/doi.org\/10.1002\/14651858.CD009849.pub3","journal-title":"Cochrane Database Syst Rev"}],"updated-by":[{"DOI":"10.1007\/s40618-026-02863-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000}}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02802-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02802-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:42Z","timestamp":1790757222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02802-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":112,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02802-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: due to the author names were incorrectly swapped in the article","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40618-026-02863-x","URL":"https:\/\/doi.org\/10.1007\/s40618-026-02863-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All Authors have no conflict of interest to declare","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}